280. 巨大動静脈奇形（頚部顔面又は四肢病変） Huge arteriovenous malformation with cervicofacial or limb lesion Clinical trials / Disease details
臨床試験数 : 25 / 薬物数 : 29 - (DrugBank : 15) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05125471 (ClinicalTrials.gov) | January 2022 | 12/11/2021 | COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM) | COBI-AVM Study - Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib In Extracranial Arteriovenous Malformations (AVM) | Arteriovenous Malformations (Extracranial) | Drug: Cobimetinib | University of Arkansas | Genentech, Inc. | Not yet recruiting | 2 Years | 80 Years | All | 17 | Phase 2 | NULL |
| 2 | ChiCTR2100048193 | 2021-07-01 | 2021-07-04 | Clinical study of bilateral uterine artery embolization versus surgical resection in the treatment of uterine arteriovenous malformation | Clinical study of bilateral uterine artery embolization versus surgical resection in the treatment of uterine arteriovenous malformation | Uterine arteriovenous malformation | Experimental group:Uterine arterial embolization;Control group:Surgical resection; | Henan Provincial People's Hospital | NULL | Pending | Female | Experimental group:10;Control group:10; | Phase 4 | China | ||
| 3 | NCT04297033 (ClinicalTrials.gov) | January 1, 2021 | 21/2/2020 | Lovastatin for Treatment of Brain Arteriovenous Malformations | Lovastatin for Treatment of Brain Arteriovenous Malformations:a Double-blind, Placebo-controlled Randomized Trial | Cerebral Arteriovenous Malformation | Drug: Lovastatin;Drug: Placebo | Beijing Tiantan Hospital | NULL | Not yet recruiting | 18 Years | N/A | All | 1244 | Phase 2 | China |
| 4 | ChiCTR2000036597 | 2020-10-01 | 2020-08-24 | The safety and efficacy of embolization of jaw arteriovenous malformations: one center observational study | The safety and efficacy of embolization of jaw arteriovenous malformations: one center observational study | jaw arteriovenous malformations | group of bleeding:coils and absolute ethanol;group of no bleeding:coils and absolute ethanol; | Shanghai Ninth People Hospital, School of Medicine, Shanghai Jiaotong University | NULL | Pending | 5 | 15 | Both | group of bleeding:30;group of no bleeding:30; | N/A | China |
| 5 | ChiCTR2000036576 | 2020-09-01 | 2020-08-24 | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute Ethanol and Onyx in the treatment of AVM | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute Ethanol and Onyx in the treatment of AVM | arteriovenous malformations | Group 1:absolute ethanol;Group 2:Oynx; | Shanghai Ninth People Hospital, School of Medicine, Shanghai Jiaotong University | NULL | Recruiting | Both | Group 1:30;Group 2:30; | N/A | China | ||
| 6 | NCT04999618 (ClinicalTrials.gov) | January 1, 2020 | 17/7/2021 | A New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology | DOUBLE-SKIN: a New Approach in Laser Surgery Using the Regenerative Solution in Children Diagnosed With Vascular Pathology: a Randomised, Double-blind, Placebo-controlled Trial | Vascular Diseases;Vascular Malformation;Capillary Malformation-Arteriovenous Malformation;Port-Wine Stain;Sturge-Weber Syndrome;Vascular Tumor | Drug: Haemoblock;Other: Placebo | Center for Vascular Pathology, Moscow | NULL | Completed | 6 Months | 18 Years | All | 200 | Phase 4 | Russian Federation |
| 7 | EUCTR2019-001530-33-FR (EUCTR) | 29/06/2019 | 01/04/2019 | TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN | TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN - TOPGUN | Lingual microcystic lymphatic malformations (LMLM) in children and adults MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Trade Name: RAPAMUNE Product Name: Sirolimus 1mg/mL Product Code: L04AA10 | CHRU TOURS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 12 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France | ||
| 8 | ChiCTR1900021901 | 2019-03-20 | 2019-03-15 | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Study | central nervous system arteriovenous malformations | Case series:Oral thalidomide; | Xuanwu Hospital, Capital Medical University | NULL | Completed | Both | Case series:30; | China | |||
| 9 | EUCTR2018-001359-11-FR (EUCTR) | 22/02/2019 | 23/07/2018 | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial | 0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICAL | Cutaneous microcystic lymphatic malformations (CMLM) in children and adults MedDRA version: 20.0;Level: LLT;Classification code 10003229;Term: Arteriovenous malformations;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15] | Product Name: Sirolimus 0,1% crème INN or Proposed INN: SIROLIMUS | CHRU TOURS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 55 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France | ||
| 10 | ChiCTR1800017616 | 2018-08-06 | 2018-08-06 | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVM | A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVM | arteriovenous malformations | Ethanol group:Embolization with ethanol;Onyx group:Embolization with Onyx;n-BCA group:Embolization with n-BCA; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | Both | Ethanol group:30;Onyx group:30;n-BCA group:30; | China | |||
| 11 | ChiCTR1800015220 | 2018-03-14 | 2018-03-15 | Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations | Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformations | arteriovenous malformations | Ethanol group:Embolization with absolute ethanol; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | Both | Ethanol group:30; | China | |||
| 12 | NCT02625389 (ClinicalTrials.gov) | November 29, 2017 | 3/12/2015 | Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. | Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study. | Congenital Hemangioma;Hemangioendothelioma;Angiosarcoma;Arteriovenous Malformation | Drug: Lipiodol® Ultra Fluid with surgical glues | Guerbet | NULL | Recruiting | 18 Years | N/A | All | 125 | Phase 4 | India |
| 13 | JPRN-UMIN000030522 | 2017/11/14 | 22/12/2017 | A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomalies | Intractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformations | Body surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day. | Gifu University | NULL | Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | |
| 14 | NCT03306836 (ClinicalTrials.gov) | September 2016 | 31/5/2017 | Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2 | Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation | Cerebral Aneurysm;Arteriovenous Malformations | Drug: Heparin Sodium | Beijing Tiantan Hospital | Tang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union Hospital | Recruiting | N/A | 70 Years | All | 408 | N/A | China |
| 15 | NCT02314377 (ClinicalTrials.gov) | June 2016 | 25/11/2014 | Bevacizumab Therapy for Brain Arteriovenous Malformation | Bevacizumab Therapy for Brain Arteriovenous Malformation | Brain Arteriovenous Malformation | Drug: Bevacizumab | University of California, San Francisco | NULL | Completed | 18 Years | 64 Years | All | 2 | Phase 1 | United States |
| 16 | ChiCTR-IOR-16008047 | 2016-03-01 | 2016-03-03 | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trial | extracranial arteriovenous malformations | bleomycin group:Intralesional Bleomycin Injection;Control group:No medicine; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | Both | bleomycin group:80;Control group:40; | China | |||
| 17 | NCT03076099 (ClinicalTrials.gov) | January 1, 2016 | 6/3/2017 | Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization | Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization | Anesthesia | Drug: Dexmedetomidine;Other: normal saline | Nan Jiang | NULL | Recruiting | 18 Years | 65 Years | All | 30 | N/A | China |
| 18 | NCT02552459 (ClinicalTrials.gov) | September 2015 | 26/5/2015 | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery | Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study | Arteriovenous Malformation | Drug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3 | First Affiliated Hospital, Sun Yat-Sen University | NULL | Recruiting | 18 Years | 65 Years | Both | 120 | Phase 4 | China |
| 19 | NCT02042326 (ClinicalTrials.gov) | September 12, 2014 | 20/1/2014 | Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations | Arteriovenous Malformations | Drug: Sirolimus | Centre Hospitalier Universitaire, Amiens | NULL | Recruiting | 2 Years | N/A | All | 50 | Phase 2 | Belgium;France |
| 20 | ChiCTR-OOB-15007258 | 2014-03-10 | 2015-10-23 | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective Study | Arteriovenous Malformation | bleomycin group:intralesional adminstrated bleomycin ; | Shanghai 9th People's Hospital, Shanghai Jiaotong University School of Medicine | NULL | Recruiting | 2 | 60 | Both | bleomycin group:30; | China | |
| 21 | NCT02496013 (ClinicalTrials.gov) | January 2014 | 6/7/2015 | Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB | Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis | Arteriovenous Malformation;Hemangioma;Neoplasms Lymph Nodes;Lymphedema | Drug: 68Ga-NEB | Peking Union Medical College Hospital | National Institute for Biomedical Imaging and Bioengineering (NIBIB) | Recruiting | 18 Years | N/A | All | 70 | Phase 1 | China |
| 22 | NCT00783523 (ClinicalTrials.gov) | March 2008 | 30/10/2008 | Influence of MMP on Brain AVM Hemorrhage | Influence of Matrix Metalloproteinase on Brain Arteriovenous Malformation Hemorrhage | Arteriovenous Malformations;Cavernous Angiomas;Brain Aneurysms | Drug: Doxycycline or Placebo | University of California, San Francisco | NULL | Completed | 13 Years | N/A | Both | 33 | Phase 1 | United States |
| 23 | NCT00389935 (ClinicalTrials.gov) | October 2006 | 17/10/2006 | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding | Arteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;Melena | Drug: Thalidomide | Northport Veterans Affairs Medical Center | Georgia Regents University;University of Massachusetts, Worcester | Completed | 18 Years | N/A | Both | 14 | Phase 2 | United States |
| 24 | NCT00243893 (ClinicalTrials.gov) | July 2004 | 24/10/2005 | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and Aneurysms | Aneurysms;Arteriovenous Malformations | Drug: minocycline;Drug: doxycycline | University of California, San Francisco | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | 13 Years | 80 Years | Both | 26 | Phase 1 | United States |
| 25 | EUCTR2019-003573-26-BE (EUCTR) | 18/12/2019 | Evaluating the safety and efficacy of Trametinib in Arterio-Venous Malformations that are refractory to standard care | Monocentric pilot trial evaluating efficacy of Trametinib in Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated - TRAMAV | Arteriovenous Malformations that are refractory to standard treatments or for which standard treatment are contra-indicated;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Mekinist Product Name: Mekinist | Cliniques universitaires Saint-Luc | NULL | NA | Female: yes Male: yes | 20 | Phase 2 | Belgium |